Anti-malarial pharmaceutical composition

31-05-2014 дата публикации

Номер:

AP0000002920A

Автор: BOOLES CLIVE [GB], ROSS CALVIN [GB], SAMS MARTIN [GB], BOOLES CLIVE, ROSS CALVIN, SAMS MARTIN

Принадлежит: Protopharma Ltd

Контакты:

Номер заявки: 05-00-2010231

Дата заявки: 27-10-2008

[1]

Patents Granted (Contd.)

[2]

(11) Patent No:

(21)	Application No :	AP/P/2010/005231
(22)	Filing Date :	27.10.2008
(24)	Date of Grant &	19.05.2014
(45)	Publication :

[3]

FORM 25

[4]

(12) PATENT

[5]

(19) AP

[6]

AP 2920

[7]

(30) Priority Data

[8]

(33) Country (31) Number (32) Date

[9]

GB 0720967.9 25.10.2007

[10]

GB 0806510.4 10.04.2008

[11]

(84) Designated State

[12]

BW GM GH KE LS LR MW MZ NA

[13]

SL SD SZ TZ UG ZM ZW

[14]

(73) Applicant(s)

PROTOPHARMA LIMITED

[15]

Norwich Bio-Incubator, Norwich Research Park, Colney Lane, Norwich, Norfolk NR4 7UH, United Kingdom

[16]

(72) Inventors

[17]

BOOLES Clive, United Kingdom

[18]

ROSS Calvin, United Kingdom

[19]

SAMS Martin, United Kingdom

[20]

et al

[21]

(74) Representative

[22]

HONEY 8c BLANCKENBERG

[23]

(51) International Classification i

[24]

A61K 9/00 (2006.01)

[25]

A61K31/357(2006.01)

[26]

A61K47/44 (2006.01)

[27]

A61P33/06 (2006.01)

[28]

(54) Title

[29]

Anti-malarial pharmaceutical composition

[30]

(57) Abstract

[31]

The invention provides pharmaceutical compositions for the treatment and prophylaxis of malaria, comprising artemether and a medium chain

[32]

triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the

[33]

compositions.

[34]

[35]

(56) Documents Cited : US 2003/203875 Al WO 2007/043057 A US 2004/038933 Al TOUITOU et al NAVARATNAM V et al

[36]

The invention provides pharmaceutical compositions for the treatment and prophylaxis of malaria, comprising artemether and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions.

A pharmaceutical composition for use in a method of preventing or treating malaria, said composition comprising:

artemether or arteether; and

a pharmaceutically-acceptable excipient selected the group consisting of:

medium chain length triglycerides;

short chain triglycerides;

omega-3-marine triglycerides; and

fish oil, rich in omega-3-acids

said composition formulated for transmucosal sublingual, buccal or nasal dosage.

A composition for use according to claim 1 wherein said composition consists essentially of:

artemether or arteether; and

one or more pharmaceutically-acceptable excipients selected the group consisting of:

medium chain length triglycerides;

short chain triglycerides;

omega-3-marine triglycerides; and

fish oil, rich in omega-3-acids

said composition formulated for transmucosal sublingual, buccal or nasal dosage.

A composition for use according to claim 1 wherein said composition consists essentially of:

artemether or arteether; and

a pharmaceutically acceptable excipient consisting essentially of:

a triglyceride, liquid at 37°C; and

medium chain length triglycerides;

said composition formulated for transmucosal sublingual, buccal or nasal dosage.

A composition for use according to any preceding claim wherein said composition is substantially free of water.

A composition for use according to any preceding claim wherein said composition is substantially free of ethanol.

A composition for use according to any preceding claim where in said composition artemether or arteether is present at a concentration of between 2 and 250 milligrams per gram of excipient.

A composition for use according to any preceding claim where in said composition said excipient comprises a medium chain triglyceride, said triglyceride comprising a minimum of 95 per cent of saturated fatty acids with between 6 and 12 carbon atoms.

A composition for use according to claim 7 wherein said excipient comprises a medium chain triglyceride, said triglyceride comprising a minimum of 95 per cent of saturated fatty acids with between 8 and 10 carbon atoms.

A composition for use according to any preceding claim wherein said composition further comprises an essential oil such as menthol, vanillin or orange oil, lemon oil, clove oil, peppermint oil, spearmint oil.

A composition for use according to any preceding claim wherein said composition is formulated for sublingual delivery.

CPC - классификация

A A6 A61 A61K A61K3 A61K31 A61K31/A61K31/3 A61K31/35 A61K31/357 A61K31/36 A61K31/365 A61K4 A61K47 A61K47/A61K47/1 A61K47/10 A61K47/14 A61K47/4 A61K47/44 A61K9 A61K9/A61K9/0 A61K9/00 A61K9/004 A61K9/0043 A61K9/006 A61K9/007 A61K9/0073 A61M A61M1 A61M11 A61M11/A61M11/0 A61M11/00 A61M11/001 A61M11/006 A61M15 A61M15/A61M15/0 A61M15/00 A61M15/009 A61M3 A61M39 A61M39/A61M39/2 A61M39/22 A61P A61P3 A61P33 A61P33/A61P33/0 A61P33/00 A61P33/06 Y Y0 Y02 Y02A Y02A5 Y02A50 Y02A50/Y02A50/3 Y02A50/30

IPC - классификация

A A6 A61 A61K A61K3 A61K31 A61K31/A61K31/3 A61K31/35 A61K31/357 A61K4 A61K47 A61K47/A61K47/4 A61K47/44 A61K9 A61K9/A61K9/0 A61K9/00 A61P A61P3 A61P33 A61P33/A61P33/0 A61P33/06

Цитирование НПИ

NAVARATNAM V. ET AL.: "PHARMACOKINETICS OF ARTEMISININ-TYPE COMPOUNDS" CLINICAL PHARMACOKINETICS, ADIS INTERNATIONAL LTD., AUCKLAND, NZ, vol. 39, no. 4, 1 October 2000 (2000-10-01), pages 255-270
TOUITOU E, et al. 'Treatment of malaria in a mouse model by intranasal drug administration,' International Journal for Parasitology, (2006) Vol 36 pp 1439-1498
US 20030203875 A1 HARTELL MARK G, et al 20031030
US 20040038933 A1 KANEKO YUTARO, et al 20040226
WO 2007043057 A2 YISSUM RES DEV CO, et al 20070419